{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-085887","form_type":"8-K","ticker":"OGN","cik":"0001821825","company_name":"Organon & Co.","filed_at":"2022-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.227318+00:00","generated_at":"2026-06-24T04:27:12.552563+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Organon Q2 revenues $1.585B (-1% as-reported, +5% ex-FX); adj EPS $1.25; FY guidance narrowed","bullets":["Q2 revenues $1,585M, down 1% as-reported but up 5% ex-FX vs Q2 2021; diluted EPS $0.92, adj diluted EPS $1.25 (both include -$0.30 IPR&D).","Adjusted EBITDA $512M (32.3% margin), inclusive of $97M acquired IPR&D and milestones.","Board declares quarterly dividend $0.28/share (unchanged).","Full-year 2022 revenue guidance narrowed to $6.1B-$6.3B; adj EBITDA margin 32%-34% reflecting FX and IPR&D.","Biosimilars revenue +42% ex-FX; Established Brands +4% ex-FX; Women's Health +1% ex-FX."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-085887","json":"https://secwatch.observer/filing/0001104659-22-085887.json","markdown":"https://secwatch.observer/filing/0001104659-22-085887.md","text":"https://secwatch.observer/filing/0001104659-22-085887.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821825/000110465922085887/0001104659-22-085887-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821825/000110465922085887/tm2222382d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T04:27:12.552563+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}